Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results